Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
300.2 USD | -1.85% | -4.66% | +4.23% |
May. 28 | US FDA approves Amgen's biosimilar to AstraZeneca's rare blood disorder treatment | RE |
May. 28 | Amgen's Rare-Disease Treatment Biosimilar Bkemv Gets FDA Approval | DJ |
Financials (USD)
Sales 2024 * | 33B | Sales 2025 * | 33.96B | Capitalization | 161B |
---|---|---|---|---|---|
Net income 2024 * | 4.13B | Net income 2025 * | 6.52B | EV / Sales 2024 * | 6.36 x |
Net Debt 2024 * | 48.72B | Net Debt 2025 * | 43.88B | EV / Sales 2025 * | 6.03 x |
P/E ratio 2024 * |
37.8
x | P/E ratio 2025 * |
24.3
x | Employees | 26,700 |
Yield 2024 * |
3.08% | Yield 2025 * |
3.33% | Free-Float | 99.75% |
Latest transcript on Amgen Inc.
1 day | -1.85% | ||
1 week | -4.66% | ||
Current month | +9.58% | ||
1 month | +11.19% | ||
3 months | +8.19% | ||
6 months | +13.06% | ||
Current year | +4.23% |
Managers | Title | Age | Since |
---|---|---|---|
Robert Bradway
CEO | Chief Executive Officer | 61 | 06-05-31 |
Peter Griffith
DFI | Director of Finance/CFO | 65 | 19-10-22 |
James Bradner
CTO | Chief Tech/Sci/R&D Officer | 52 | Dec. 17 |
Members of the board | Title | Age | Since |
---|---|---|---|
Charles Holley
BRD | Director/Board Member | 67 | 17-02-02 |
Ellen Kullman
BRD | Director/Board Member | 68 | 16-10-13 |
Robert Williams
BRD | Director/Board Member | 75 | 14-10-16 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
7.84% | 0 M€ | 0.00% | - | |
7.63% | 0 M€ | 0.00% | - | |
5.08% | 116 M€ | +14.55% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-28 | 300.2 | -1.85% | 2,636,709 |
24-05-24 | 305.8 | -0.22% | 2,425,864 |
24-05-23 | 306.5 | -0.94% | 2,139,729 |
24-05-22 | 309.4 | -1.73% | 2,849,114 |
24-05-21 | 314.8 | +0.10% | 1,705,945 |
Delayed Quote Nasdaq, May 28, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.23% | 161B | |
+38.59% | 727B | |
-7.89% | 347B | |
+15.66% | 319B | |
+0.24% | 274B | |
+13.47% | 238B | |
+7.35% | 204B | |
-6.42% | 203B | |
-1.70% | 160B | |
-1.31% | 120B |
- Stock Market
- Equities
- AMGN Stock